Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

First CF patient dosed with molecular prosthetic CM001

The first person with cystic fibrosis (CF) has been dosed with CM001, an experimental inhaled therapy being developed by Cystetic Medicines to treat all people with CF, including those who aren’t eligible for modulators. “Dosing the first person with CF represents a critical milestone in our mission to…

Chloride-transporting synthetic molecules show promise

Researchers have developed new synthetic molecules that can transport chloride salts across cell membranes, which showed promise for restoring normal mucus production in a cell model of cystic fibrosis (CF), a new study shows. “One day, [these molecules] could be leveraged into a drug that treats cystic fibrosis,” Bing…

Low T common, but likely underdiagnosed, in men with CF

Men with cystic fibrosis (CF) commonly have low testosterone levels, though this is likely underrecognized due to a lack of testing, a new study highlights. The findings underscore the importance of checking testosterone levels in men with CF so that interventions can be discussed if warranted, researchers said in…

Achromobacter bacteria seen as new target to fight CF infections

A type of bacteria called Achromobacter, which can cause problematic lung infections in people with cystic fibrosis (CF), uses a molecular weapon — one known as a type 3 secretion system — to induce a powerful inflammatory response during infections, a new study found. “These bacteria resist the action…